Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016.
Krisztina Bogos, Zoltan Kiss, Lilla Tamási, Gyula Ostoros, Veronika Müller, László Urbán, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Zoltán Polányi, Zsófia Nagy-Erdei, Andrea Daniel, Zoltán Vokó, Balázs Nagy, Krisztián Horváth, György Rokszin, Zsolt Abonyi-Tóth, Zsófia Barcza, Gabriella Gálffy and Judit Moldvay (Pathology & Oncology Research, doi: 10.3389/pore.2021.603937)
Lung cancer is one of the most common cancers worldwide and its survival is still poor. The objective of our study was to estimate long-term survival of Hungarian lung cancer patients at first time based on a nationwide review of the National Health Insurance Fund database.
Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between January 1, 2011 and December 31, 2016. Survival rates were evaluated by year of diagnosis, patient gender and age, and morphology of lung cancer.
41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and 65.9 years during study period. One- and 5-year overall survival rates for the total population were 42.2 and 17.9%, respectively. Survival was statistically associated with gender, age and type of lung cancer. Female patients (n=16,362) had 23% better survival (HR: 0.77, 95% confidence interval (CI): 0.75–0.79; p <0.001) than males (n=25,492). The highest survival rates were found in the 20–49 age cohort (5Y=31.3%) and if the cancer type was adenocarcinoma (5Y=20.5%). We measured 5.3% improvement (9.2% adjusted) in lung cancer survival comparing the period 2015–2016 to 2011–2012 (HR: 0.95 95% CI: 0.92–0.97; p=0.003), the highest at females <60 year (0.86 (adjusted HR was 0.79), interaction analysis was significant for age and histology types.
Our study provided long-term Lung cancer survival data in Hungary for the first time. We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients had better survival. Survival rates were comparable to–and at the higher end of–rates registered in other East-Central European countries (7.7%–15.7%).